Amy Dyken, controller at Fitzgerald Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Fitzgeralds financial statements. Below is selected financial information for the fiscal year ended June 30, 2014.

FITZGERALD PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2014
Long-term debt
Notes payable, 9%		$1,077,000
7% convertible bonds payable		5,178,000
9% bonds payable		6,003,000
Total long-term debt		$12,258,000
Shareholders equity
Preferred stock, 5% cumulative, $60 par value, 100,400 shares authorized, 25,100 shares issued and outstanding		$1,506,000
Common stock, $1 par, 10,026,000 shares authorized, 1,002,600 shares issued and outstanding		1,002,600
Additional paid-in capital		4,012,600
Retained earnings		6,004,300
Total shareholders equity		$12,525,500

The following transactions have also occurred at Fitzgerald.

1.		Options were granted on July 1, 2013, to purchase 209,400 shares at $18 per share. Although no options were exercised during fiscal year 2014, the average price per common share during fiscal year 2014 was $25 per share.
2.		Each bond was issued at face value. The 7% convertible bonds will convert into common stock at 60 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2013.
3.		The preferred stock was issued in 2013.
4.		There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2014.
5.		The 1,002,600 shares of common stock were outstanding for the entire 2014 fiscal year.
6.		Net income for fiscal year 2014 was $1,545,000, and the average income tax rate is 40%.

For the fiscal year ended June 30, 2014, calculate the following for Fitzgerald Pharmaceutical Industries.

A. Basic earnings per share

B. Diluted earnings per share